NASDAQ:RCMR1 RCM Stock Price, Forecast & News

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RCM shares have increased by 19.5% and is now trading at $12.14. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for R1 RCM.

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for R1 RCM.

R1 RCM Inc (NASDAQ:RCM) announced its earnings results on Tuesday, May, 5th. The healthcare provider reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.03. The healthcare provider earned $320.50 million during the quarter, compared to the consensus estimate of $318.76 million. R1 RCM had a net margin of 2.44% and a return on equity of 174.42%. The business's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.04) earnings per share. View R1 RCM's earnings history.

6 analysts have issued twelve-month price targets for R1 RCM's stock. Their forecasts range from $10.00 to $17.00. On average, they expect R1 RCM's share price to reach $13.83 in the next year. This suggests a possible upside of 13.9% from the stock's current price. View analysts' price targets for R1 RCM.

Media headlines about RCM stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. R1 RCM earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave news coverage about the healthcare provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about R1 RCM.

Some companies that are related to R1 RCM include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), Alibaba Group (BABA), JD.Com (JD), Baozun (BZUN), Marvell Technology Group (MRVL), Model N (MODN), Baidu (BIDU), BioDelivery Sciences International (BDSI), Perficient (PRFT) and RingCentral (RNG).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RCM stock can currently be purchased for approximately $12.14.

R1 RCM has a market capitalization of $1.39 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe.

The official website for R1 RCM is www.r1rcm.com.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected]